Mysterious OrbiMed-backed biotech nears $100M in funding, hints at plans to go after ‘undruggable 3.0’
In January, Alterome launched from stealth — but remained quite stealthy. While the biotech put out a press release for its $64 million Series A, led by OrbiMed, it launched without a website and didn’t elaborate on its science beyond “alteration-specific targeted therapies for the treatment of cancer.”
But with an additional $35 million — bringing its total Series A to $99 million — Alterome appears more willing to share. For one, it now has a website, although the page doesn’t offer more than the bare-bones details on the science.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.